UNSPSC 51263303: Butidrine

This classification denotes an adrenergic antagonist with the molecular formula C16H25NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N2S0PKP5L5, chemically known as 5,6,7,8-tetrahydro-alpha-(((1-methylpropyl)amino)methyl)-2-naphthalenemethanol hydrochloride but generally known as butidrine, which bears US NIH Compound Identifier 15176. Butidrine most often comes in base and hydrochloride forms. European Medicines Agency schedules Butidrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06016MIG.

UNSPSC 51263303 Butidrine is a Commodity code that, based on recent state and local solicitation activity, covers naloxone and drug deactivation systems procurement for public health and emergency response programs. State and local governments soliciting under this code are acquiring naloxone kits and safe drug deactivation equipment to support community health initiatives, overdose response, and pharmaceutical waste management. The issuing bodies span county health departments and state health and human services agencies, with Seminole County, Florida and the Texas Health and Human Services Commission posting recent opportunities. These jurisdictions are moving toward systematic procurement of naloxone supply chains and exploring direct-to-manufacturer contracting models to improve fulfillment efficiency and cost management in pharmacy benefit programs.

Seminole County, Florida has posted the most concrete recent opportunity: IFB 60459723LAS, an Invitation for Bid posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, and a two-year contract term with one-year renewal option. Quarterly deliveries are required to the Seminole County Community Health Building in Sanford, with vendors responsible for shipping and delivery costs. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription and pharmaceutical supply programs; this exploratory solicitation does not carry a binding timeline or award value but signals state-level intent to restructure pharmacy benefit procurement. Both opportunities reflect growing demand across Florida and Texas for naloxone and related drug-management systems at the county and state level.